Optimal treatment of breast cancer in women older than 75 years: a Korea Breast Cancer Registry analysis

Ye Won Jeon1 · Sun Hyong You2 · Jong Eun Lee3 · Hyun Jo Youn4 · Woosung Lim5 · Jai Hong Han6 · Chan Heun Park7 · Yong Seok Kim8

Received: 17 August 2019 / Accepted: 27 August 2019 / Published online: 6 September 2019
© The Author(s) 2019

Abstract
Purpose The aim of this study was to investigate the therapeutic efficacy of adjuvant modalities for elderly Asian breast cancer patients using population-based data from the Korean Breast Cancer Registry database.

Methods We identified 53,582 patients who underwent curative surgery between January 2005 and December 2010. The primary end point was the comparison of overall survival between the administration or omission of adjuvant treatment modalities, including endocrine treatment, radiation therapy, and chemotherapy, in the elderly group (older than 75 years) compared with the control group (younger than 75 years).

Results Of the 53,582 patients analyzed, the total number of elderly patients was 901 (1.7%), and the number of control patients was 52,681 (98.3%). Although elderly patients were found to have larger tumor sizes ($p = 0.024$) and higher pathological stages ($p < 0.001$) than the control group, elderly patients were less likely to undergo adjuvant treatment compared to the control group. However, use of endocrine treatment in elderly patients with HR-positive breast cancer is associated with improved overall survival (OS) (adjusted OR 0.417; 95% confidence interval [CI] 0.240–0.726; $p = 0.002$). Furthermore, chemotherapy was associated with a significant improvement in OS in patients with stage II and III breast cancer (adjusted OR 0.657; 95% CI 0.462–0.934; $p = 0.019$).

Conclusion Endocrine treatment and chemotherapy for elderly patients are associated with improved OS. Therefore, personalized decision-making based on the potential survival benefit of adjuvant treatment modalities should be made with the careful counseling of all elderly patients with breast cancer.

Keywords Breast neoplasms · Elderly women · Adjuvant treatment · Survival

Introduction

Life expectancy has increased in recent decades due to developments in public health and medical science. Individuals aged 65 years and older are the fastest growing segment
of Western regions, with people over the age of 75 years projected to comprise a disproportionate part of the USA population by 2030 [1, 2]. This phenomenon is also occurring in Asia. According to the Statistics Korea, life expectancy of a 75-year-old women was 11.6 years in 2005 and has extended up to 13.9 years in 2016 [3]. As the population life expectancy increases, the proportion of elderly patients with various malignancies has increased.

Breast cancer, which is the most commonly diagnosed cancer in Western and Korean women, is no exception to this trend. Incidence rates increase with age, with over 30% of cases diagnosed in women over 70 years in Western regions [1, 4]. According to reports from Statistics Korea(KOSTAT), the proportion of breast cancer diagnoses in women aged more than 70 years was 5.2% in 2004, and this proportion increased to 8.8% in 2015 [5]. However, despite the increasing proportion of elderly patients with breast cancer, standard therapeutic guidelines for this patient population are inconsistent, leading to challenges for clinicians in managing elderly patients. From previous publications, clinicians who manage elderly breast cancer patients should consider their functional status, comorbidities, clinical stages, biological characteristics of the cancer, and life expectancy [6–8]. The results of these considerations may lead to the under-treatment of elderly patients compared with younger patients [6, 9, 10]. Clinicians who manage elderly patients are required to choose the proper adjuvant modalities, such as endocrine treatment, radiation therapy, and chemotherapy, to maximize the efficacy of cure and maintain disease free status while, at the same time, minimizing interruptions in quality of life and unexpected early death.

Moreover, there are certain differences between Asian and Western regions with respect to age-specific incidence rates of breast cancer [11]. As the peak incidence age (35–64 years) of breast cancer in Korea is younger compared with Western regions (aged 65 year and older) [11, 12], the incidence of breast cancer in women older than 75 years at diagnosis is relatively low in Korea. Because the subgroup of patients older than 75 years would be too small, individual hospital-based registries would be inadequate to effectively address proper adjuvant modalities in elderly patients.

Therefore, the aim of this study was to investigate the characteristics of elderly breast cancer patients (aged 75 years and older) compared with non-elderly patients (control patients, less than 75 years old) and the therapeutic efficacy of adjuvant modalities (endocrine treatment, radiation therapy and chemotherapy) for elderly Asian breast cancer patients using population-based data from the Korean Breast Cancer Registry database.

Methods

Korean Breast Cancer Registry (KBCR)

The KBCR database was previously described in detail [13]. Briefly, the KBCR database is a Web-based, prospectively maintained nationwide database managed by the Korean Breast Cancer Society (KBCS). One hundred and two institutions have voluntarily participated in this registry since 1997. Before inserting personal information, along with various datasets, written informed consent is mandatory from the patient. From the initial conception of the KBCR database, principal investigators from every institution have agreed on the principles and processes of utilizing this database for research purposes. Essential registry items include patient age, sex, surgical method used, and breast cancer stage according to the seventh edition of the American Joint Committee on Cancer classification [14], biological status (hormone receptor [HR] and human epidermal growth factor receptor 2 [HER2]) and adjuvant treatment (endocrine treatment, radiation therapy and chemotherapy). The Korean Central Cancer Registry provides only mortality data, and the KBCR does not include information on tumor recurrence. According to the guidelines of utilizing the KBCR database, this study was approved by the Institutional Review Board (IRB) of Uijeongbu St. Mary’s Hospital, Catholic University of Korea (UC18RCSE0045). The KBCS approved our research objective and request for data in March 2018.

From the KBCS registry, we assessed female patients with invasive breast cancer who underwent curative surgery between January 2005 and December 2010. To achieve a more accurate analysis, we excluded patients treated with neoadjuvant therapy and patients for whom essential registry data (gender, age, and cancer stage) were not available. Patients with distant metastasis (stage IV) and advanced stage (stage IIc) at the time of diagnosis were excluded because these stages have the worst prognosis compared to other prognoses and serve as confounding factors for survival analysis. See Fig. 1 for a detailed list of excluded cases.

Data on the remaining 53,582 patients were included in the final analysis. All patients were categorized into one of two subgroups based on their age: elderly patients (≥75 years old) versus control patients (<75 years old).

Statistics

The means and standard deviations of physiological and demographic characteristics were calculated. A t test was used to compare the means when there were 2 categories.
Proportions were compared using two-way tables and Chi-square tests. Survival curves were estimated using the Kaplan–Meier method, and log-rank tests were performed for comparison of survival curves. The primary end point was the comparison of overall survival between the administration and omission of adjuvant treatment modalities, including endocrine treatment, radiation therapy, and chemotherapy, in elderly patients. Overall survival (OS) was defined as the time from initial diagnosis of primary breast cancer to death from any cause. Multivariate analyses were conducted using a Cox proportional hazard regression model to study the effects of each therapeutic modality (endocrine treatment, radiation therapy and chemotherapy) on OS. Parameters included in the multivariate analysis model were as follows: breast surgery type, breast cancer stage, endocrine treatment, radiation therapy, and chemotherapy. All tests were two-sided, and a p value < 0.05 was considered to be statistically significant. All statistical analyses were performed using IBM SPSS software version 22.0 for Windows (IBM Corp., Armonk, USA).

Results

Patient characteristics

According to the eligibility criteria, we identified 53,582 patients who underwent curative surgery between January 2005 and December 2010 from the KBCS registry. The total number of elderly patients was 901 (1.7%), and the number of control patients was 52,681 (98.3%). Clinical and pathological characteristics are listed in Table 1.

The median age of patients in the elderly group was 77 years (range 75–94 years) and that of the control group was 48 years (range 20–74 years). Compared with the control group, the elderly group was more likely to undergo mastectomy (p < 0.001) and was less likely to undergo axillary surgery (p = 0.005). Elderly patients were found to have larger tumor sizes (2.280 ± 1.74 cm vs. 2.017 ± 3.35 cm, p = 0.024) and higher pathological stages (p < 0.001) than the control group. HR and HER-2 status were different between the elderly and control groups, with the elderly group having a higher rate of the HR(+)/HER2(−) subtype (p < 0.001).

The median follow-up for survival analysis was 69 months (range 5–134 months) in the elderly group and 77 months (range 5–119 months) in the control group. Three hundred and seventeen (35.2%) cases experienced death in the elderly group, and 4934 (9.4%) cases experienced death in the control group, during the study period. The cause of death in the elderly group is listed in Table 2. Despite the 157 cases of missing data for cause of death, the most prevalent cause of death in elderly patients was breast cancer (98 cases, 61.3% of all deaths), and the second most prevalent cause of death was other malignant disease (23 cases, 14.4% of all deaths).

The life expectancy in elderly patients was analyzed and is shown in Table 3. Age ranges were subdivided into three categories (75–78, 79–83, and ≥ 84 years) according to patient distribution (60.7%, 29.6%, 9.7% each). Mean life expectancy of the entire elderly group was 121.51 months, which is approximately 10 years.
Role of endocrine treatment in elderly HR-positive breast cancer patients

To examine the therapeutic efficacy of adjuvant endocrine treatment in HR-positive patients, we extracted data for adjuvant endocrine treatment in HR-positive patients. From the registry, 471 patients in the elderly group and 28,511 patients in the control group were HR-positive breast cancer patients (Table 1). Among these patients, adjuvant endocrine treatment was administered to 342 (72.6%) patients in the elderly group and 26,292 (92.2%) patients in the control group. When compared with the control group, HR-positive elderly patients were less likely to undergo adjuvant endocrine treatment (72.6% vs 92.2%, \( p < 0.001 \)).

Notably, in the survival analysis (Fig. 2a, b), adjuvant endocrine treatment conveys statistically significant overall survival gains in both groups (elderly group: \( p = 0.023 \); control group: \( p < 0.001 \)). Furthermore, adjuvant endocrine treatment was an effective treatment option in elderly HR-positive breast cancer patients based on the multivariate analysis (adjusted OR 0.417; 95% CI 0.240–0.726; \( p = 0.002 \)) (Table 4).

Role of radiation therapy in elderly patients who underwent breast-conserving surgery

We analyzed the therapeutic efficacy of adjuvant radiation therapy in patients who underwent breast-conserving surgery for initial treatment in each group. In the elderly group, 300 patients underwent breast-conserving surgery (Table 1). Among these patients, 159 (53.1%) patients received adjuvant radiation therapy, and 141 (46.9%) patients did not. In the control group, 29,304 patients underwent breast-conserving surgery. Among these patients, 27,194 (92.8%) received adjuvant radiation therapy, and 2110 (7.2%) did not. Elderly patients were less likely to undergo adjuvant radiation therapy after breast-conserving surgery compared with the control group (53.1% vs 92.8%, \( p < 0.001 \)).

In the survival analysis, radiation therapy had a statistically significant overall survival benefit in the control group (\( p < 0.001 \)) (Fig. 2c). However, adjuvant radiation

### Table 1 Clinical and pathologic characteristics of patients

| Characteristics                  | Elderly group (\( \geq 75 \) years old) | Control group (< 75 years old) | p value |
|----------------------------------|----------------------------------------|---------------------------------|---------|
| No. (%)                          | N = 901                                | N = 52,681                      |         |
| Age (years) Mean ± SD            | 78.39 ± 3.39                           | 49.23 ± 9.80                    |         |
| Median (range)                   | 77.00 (75–94)                          | 48.00 (20–74)                   |         |
| Type of breast surgery           |                                        |                                 | <0.001  |
| Breast-conserving surgery        | 300 (33.3)                             | 29,304 (55.6)                   |         |
| Mastectomy                       | 586 (65.0)                             | 22,507 (42.7)                   |         |
| Excision only                    | 8 (0.9)                                | 267 (0.5)                       |         |
| Unknown                          | 7 (0.8)                                | 603 (1.2)                       |         |
| Type of axillary surgery         |                                        |                                 | 0.005   |
| No operation                     | 130 (14.4)                             | 5777 (11.0)                     |         |
| ALND                             | 426 (47.3)                             | 24,747 (47.0)                   |         |
| SLNB                             | 170 (18.9)                             | 11,357 (21.6)                   |         |
| SLNB → ALND                      | 171 (19.0)                             | 10,265 (19.4)                   |         |
| Unknown                          | 4 (0.4)                                | 535 (1.0)                       |         |
| Tumor size, cm Mean ± SD         | 2.280 ± 1.74                           | 2.017 ± 3.35                    | <0.001  |
| Stage                            |                                        |                                 | <0.001  |
| I                                | 381 (42.3)                             | 27,715 (52.5)                   |         |
| IIA                              | 297 (33.0)                             | 14,198 (27.0)                   |         |
| IIIB                             | 120 (13.3)                             | 5988 (11.4)                     |         |
| IIIA                             | 83 (9.2)                               | 4424 (8.4)                      |         |
| IIIB                             | 20 (2.2)                               | 356 (0.7)                       |         |
| Intrinsic type                   |                                        |                                 | <0.001  |
| HR (+)/HER2(−)                   | 431 (47.8)                             | 23,799 (45.2)                   |         |
| HR (+)/HER2(+)                   | 41 (4.6)                               | 4712 (8.9)                      |         |
| HR (−)/HER2(−)                   | 127 (14.1)                             | 7008 (13.3)                     |         |
| HR (−)/HER2(+)                   | 69 (7.7)                               | 5071 (9.6)                      |         |
| Unknown                          | 233 (25.8)                             | 12,091 (23.0)                   |         |
| Follow-up, months Mean ± SD      | 69.79 ± 25.26                          | 77.70 ± 22.44                   | <0.001  |
| Median (range)                   | 69 (5–134)                             | 77 (5–119)                      |         |
| Death event                      | 317 (35.2)                             | 4934 (9.4)                      | <0.001  |

**SD** standard deviation; **ALND** axillary lymph node dissection; **SLNB** Sentinel lymph node biopsy; **HR** hormone receptor; **HER2** human epidermal growth factor receptor 2

### Table 2 Causes of death in elderly patients in the Korean Breast Cancer Registry

| Cause of death                  | Case (n) | Case (%) |
|---------------------------------|----------|----------|
| Breast cancer                   | 98       | 61.3     |
| Respiratory failure             | 5        | 3.1      |
| Cardiovascular disease          | 8        | 5.0      |
| Brain hemorrhage/infarct        | 5        | 3.1      |
| Kidney failure                  | 5        | 3.1      |
| Diabetes                        | 4        | 2.5      |
| Other malignant disease         | 23       | 14.4     |
| Senility                        | 4        | 2.5      |
| Trauma                          | 3        | 1.9      |
| Suicide                         | 1        | 0.6      |
| Unknown                         | 157      | 49.5     |
| Total                           | 317      |          |
therapy after breast-conserving surgery was not significant for overall survival benefit in elderly patients ($p = 0.123$) (Fig. 2d). Furthermore, in multivariate analysis, adjuvant radiation therapy did not show statistically significant effects on prognosis (adjusted OR 0.467; 95% CI 0.209–1.040; $p = 0.062$), even in early-stage breast cancer (Stage I–II; OR 0.594, $p = 0.258$) (Table 4).

### Role of chemotherapy in elderly patients with advanced breast cancer

We analyzed the therapeutic efficacy of adjuvant systemic chemotherapy in patients with stage II and III disease in each group. Stage II and III breast cancer were identified in 520 patients from the elderly group and in 24,966 patients from the control group (Table 1). Among these patients, adjuvant systemic chemotherapy was administered to 129 (24.9%) patients in the elderly group and 14,655 (58.7%) patients in the control group. Elderly patients with stage II and III breast cancer were less likely to undergo adjuvant systemic chemotherapy compared with those in the control group ($p < 0.001$). This result was also consistent when classified by breast cancer stage (from IIA to IIIB) (Table 5).

In the survival analysis, adjuvant systemic chemotherapy had a statistically significant overall survival benefit in the control group ($p < 0.001$) (Fig. 2e) but not in the elderly patients ($p = 0.349$) (Fig. 2f). Although the use of this treatment slightly improved overall survival in the elderly group with stage IIIA disease, the influence on survival of adjuvant systemic chemotherapy in the elderly group was not significant compared with results from the control group (Table 5). However, in the multivariate analysis, after adjusting for multiple confounders (breast surgery type, breast cancer stage, endocrine treatment, and radiation therapy), adjuvant systemic chemotherapy was an effective treatment modality that extended overall survival for elderly patients with stage II and III breast cancer (adjusted OR 0.657; 95% CI 0.462–0.934; $p = 0.019$).

### Discussion

Our study is of particular importance in light of the aging Asian population, especially in Korea, and a lack of randomized data to guide clinical decision-making for the treatment of elderly breast cancer patients. In this study, despite larger tumor sizes and higher pathologic stages occurring more often in elderly patients compared to non-elderly patients, adjuvant treatment (endocrine treatment, radiation therapy and chemotherapy) was omitted without impacting elderly patient survival. However, adjuvant endocrine treatment and chemotherapy were obviously associated with improved overall mortality for elderly breast cancer patients in population-based data from the Korean Breast Cancer Registry.

To provide more age-specific and personalized therapeutic options for elderly breast cancer patients, it is important to classify elderly patients with respect to clinical data. ‘How old is old?’ is a very difficult question to answer to distinguish an elderly person. ‘Old age’ is subjective terminology that is affected by many environmental and biological factors, such as the degree of the national healthcare system, socioeconomic status, and personal biological health, which varies by country. Furthermore, there are several difficulties in defining a numeric reference point for old age when analyzing clinical data. Life expectancy in one country can be a useful tool to represent elderly status in a society and is easy to establish as a numeric reference point when analyzing clinical data. Instead of ‘How old is the patient?’, ‘How long is the patient is expected to live?’ can suggest more objective and effective options when analyzing geriatric studies [15]. Therefore, having 10 years of natural life expectancy was considered old age (aged 75 years and older) in our study design.

Although the number of elderly breast cancer patients has increased over the last couple decades, major clinical trials and studies for breast cancer treatment are mainly focused on younger patients [15]. Such conventional study design causes elderly people to remain underrepresented
Fig. 2 Overall survival of the control (<75 years old) and the elderly (≥75 years old) groups by adjuvant modalities (hormonal therapy, radiation therapy and chemotherapy). a, c, e: control group; b, d, f: elderly group
in many clinical trials, resulting in difficulty in creating a therapeutic plan for elderly breast cancer patients. Elderly patients greater than 75 years of age are often regarded as a unique group of patients who are not willing to obey the standard therapeutic recommendations. Furthermore, under-treatment for both surgical and adjuvant treatment is more common in elderly patients than in younger patients. There are several reasons for under-treatment in elderly patients. First, old age is associated with an increased risk of systemic therapy-related toxicity. Second, tumor biology in breast cancers of elderly patients is somewhat different than in breast cancers of younger patient. Elderly patients tend to have more favorable breast cancer characteristics at diagnosis, including anatomical stage and phenotypic characteristics [7, 16, 17].

Endocrine treatments using aromatase inhibitor (AI) or tamoxifen are the most commonly used adjuvant systemic treatments in elderly patients with HR-positive breast cancer. This method has fewer complications and better compliance than any other treatment modality and is highly effective in reducing breast cancer recurrence and increasing overall survival in elderly HR-positive breast cancer patients. Although clinical studies of endocrine agents are limited in elderly patients, the median age of women enrolled in clinical trials using AIs as adjuvant treatment agents was often greater than 60 years because of the eligibility requirement of postmenopausal status [18–20]. Furthermore, these studies definitively demonstrated superior long-term efficacy and safety of AI as an initial adjuvant treatment for postmenopausal women with HR-positive breast cancer. In addition, the results from the Early Breast Cancer Clinical Trialists’ Collaborative Group (EBCTCG) overview demonstrated decreased risk of breast cancer recurrence and death in women aged 70 years and older with early-stage HR-positive breast cancer receiving 5 years of tamoxifen, similar to that observed in younger patients [21]. This result was consistent with our current study, which found a survival benefit of

### Table 4
Multivariate analysis by Cox proportional hazard model in the elderly group

| Variable                  | OR   | 95% CI          | p value |
|---------------------------|------|-----------------|---------|
| Type of breast surgery    |      |                 |         |
| BCS                       | 1    |                 |         |
| Mastectomy                | 1.844| 1.206–2.819     | 0.005   |
| Excision                  | 6.299| 2.526–15.705    | <0.001  |
| TNM stage                 |      |                 |         |
| Stage I                   | 1    |                 |         |
| Stage II                  | 1.878| 1.278–2.759     | 0.001   |
| Stage III                 | 4.928| 3.127–7.764     | <0.001  |
| Hormonal treatment        |      |                 |         |
| No                        | 1    |                 |         |
| Yes                       | 0.417| 0.240–0.726     | 0.002   |
| Radiation therapy         |      |                 |         |
| No                        | 1    |                 |         |
| Yes                       | 0.467| 0.209–1.040     | 0.062   |
| Chemotherapy              |      |                 |         |
| No                        | 1    |                 |         |
| Yes                       | 0.657| 0.462–0.934     | 0.019   |

OR odds ratio, CI confidence interval, BCS breast-conserving surgery

### Table 5
Mean survival analysis of study groups with or without chemotherapy according to breast cancer stage (AJCC 7th edition)

| Stage      | Chemotherapy | Case (%) | Mean survival (95% CI) | p value |
|------------|--------------|----------|------------------------|---------|
| Elderly group |              |          |                        |         |
| Stage IIA  | No           | 219 (73.9)| 98.973 ± 2.559 (93.958–103.988) | 0.482   |
|            | Yes          | 78 (26.1)| 93.007 ± 4.563 (84.063–101.950) |         |
| Stage IIB  | No           | 97 (78.3)| 87.756 ± 4.275 (79.377–96.136) | 0.733   |
|            | Yes          | 26 (21.7)| 76.847 ± 6.857 (63.407–90.287) |         |
| Stage IIIA | No           | 39 (46.8)| 71.312 ± 7.559 (56.497–86.127) | 0.049   |
|            | Yes          | 44 (53.2)| 89.457 ± 6.928 (75.879–103.035) |         |
| Stage IIIB | No           | 14 (68.8)| 68.652 ± 10.471 (48.128–89.175) | 0.059   |
|            | Yes          | 6 (31.2)| 37.000 ± 3.362 (30.411–43.589) |         |
| Control group |              |          |                        |         |
| Stage IIA  | No           | 1533 (10.8)| 112.619 ± 0.631 (111.382–113.856) | 0.185   |
|            | Yes          | 12,665 (89.2)| 113.527 ± 0.199 (113.136–113.918) |         |
| Stage IIB  | No           | 251 (4.2)| 100.200 ± 2.495 (95.310–105.089) | <0.001  |
|            | Yes          | 5737 (95.8)| 110.295 ± 0.362 (109.587–111.004) |         |
| Stage IIIA | No           | 124 (2.8)| 93.349 ± 3.845 (85.813–100.885) | <0.001  |
|            | Yes          | 4300 (97.2)| 105.019 ± 0.517 (104.006–106.031) |         |
| Stage IIIB | No           | 25 (7.1)| 83.899 ± 7.686 (68.834–98.965) | 0.091   |
|            | Yes          | 331 (92.9)| 84.548 ± 2.611 (79.432–89.665) |         |

CI confidence interval
adjuvant endocrine treatment for elderly patients with HR-positive breast cancer.

Radiation therapy is a highly effective method to destroy cancer cells and to reduce local recurrence in the breast or nearby lymph nodes that may persist after breast surgery. Although adjuvant radiation therapy after breast-conserving surgery is considered standard of care, radiation therapy does not improve overall survival for many elderly breast cancer patients, as reported in previous studies [22, 23]. Furthermore, a meta-analyses of radiotherapy trials by the EBCTCG showed that the 5-year absolute reduction rate in local recurrence associated with radiation therapy was 17% in younger and 18% in older age groups [24]. Therefore, the National Comprehensive Cancer Network guidelines suggest that adjuvant radiation therapy after breast-conserving surgery may be omitted for breast cancer patients who are older, have limited life expectancy, or have favorable tumor characteristics [15]. Although the current study did not demonstrate a risk reduction benefit for adjuvant radiation therapy on local recurrence in elderly patients, our study reveals that adjuvant radiation therapy after breast-conserving surgery is not statistically significant for overall survival benefit in elderly patients by multivariate analysis.

Similar to young patients, chemotherapy is an important systemic adjuvant treatment option for elderly breast cancer patients. However, research on the impact of chemotherapy on survival outcomes in elderly patients is limited, as clinical trials typically exclude this group. Furthermore, chemotherapy-related complications, including cardiotoxicity, acute myelogenous leukemia (AML)/myelodysplastic syndromes (MDS), and death, cause elderly patients to be under-treated [15, 25, 26]. Despite these limitations, meta-analyses of randomized trials by the EBCTCG demonstrated clear evidence of a benefit for patients receiving chemotherapy aged 50–69 years at diagnosis, especially those with estrogen receptor-poor tumors [27]. A recent analysis of retrospective English cancer registration data showed that chemotherapy is associated with improved breast cancer-specific survival in elderly women (aged 70–79 years) with early breast cancer at high risk of recurrence [28]. In our study, adjuvant systemic chemotherapy was an effective treatment modality that extended overall survival for elderly patients with stage II and III breast cancer.

Although we adjusted for all possible and available factors in our analysis, our study was limited by the information available in the KBCR database. First, this study carries a risk of selection bias, and the results were lacking information on locoregional recurrence, distant metastasis, and breast cancer-specific survival. Although we did not investigate the disease free survival rate according to adjuvant modalities (endocrine treatment, radiation therapy and chemotherapy) in elderly patients, we believe that analyzing these factors would not change the power of our study because the overall survival rate is an acceptable and powerful endpoint in oncology. Further limitations include the lack of specific data on endocrine treatments (regimens, treatment period, etc.), radiation therapy (dose, field, etc.), and chemotherapy (regimens, dosage, etc.). In addition, the reasons for under-treatment of elderly patients, including physician discretion, presence of underlying comorbid conditions, socioeconomic and lifestyle factors, and patient preference, could not be evaluated in this study due to limitations of the KBCR database. Finally, the ethnic homogeneity of the KBCR database may limit the generalizability of our findings to other racial and ethnic groups.

Conclusion

In conclusion, using population-based data from the Korean Breast Cancer Registry database, this study shows that elderly patients (aged 75 years and older) with breast cancer are more likely than non-elderly patients (<75 years old) to be diagnosed at a later stage of disease and are less likely to undergo adjuvant treatment, including endocrine treatment, radiation therapy and chemotherapy. However, use of endocrine treatment in elderly patients with HR-positive breast cancer and chemotherapy in elderly patients with stage II and III breast cancer are associated with improved overall survival. Although it is not possible to determine the survival benefit of adjuvant treatment without additional information on underlying comorbidities and functional status, these data suggest that endocrine treatment in elderly patients with HR-positive breast cancer and chemotherapy for elderly patients with stage II and III breast cancer are associated with improved OS. Therefore, physicians must undertake personalized decision-making for individual patients according to reasonable estimates of predicted life expectancy, effect of certain treatments on mortality, and side effects associated with particular treatments when counseling elderly patients with breast cancer.

Acknowledgements This article was supported by the Korean Breast Cancer Society.

Funding This work received no funding

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board.
Breast Cancer Research and Treatment (2019) 178:693–701

(UC18RCE0045).

Informed consent Informed consent was obtained from all individual participants included in this study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Yancik R, Ries LA (2004) Cancer in older persons: an international issue in an aging world. Semin Oncol 31:128–136
2. Freedman RA (2015) Treatment of breast cancer in the elderly. Curr Oncol Rep 17:51
3. Statistics Korea. Statistic explanation DB. Daejeon: Statistics Korea, http://kosis.kr/statHtml/statHtml.do?orgId=101&tblId=DT_1B41&vw_cd=MT_ZTITLE&list_id=A5&seqNo=&lang_mode=ko&language=kor&obj_var_id=&itm_id=&conn_path=MT_ZTITLE. Accessed 17 July 2019
4. Cancer Research UK. Cancer statistics reports for the UK. http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsrepo rt. Accessed 17 July 2019
5. Kang SY, Kim YS, Kim Z, Kim HY, Lee SK, Jung KW et al (2018) Basic findings regarding breast cancer in Korea in 2015: data from a breast cancer registry. J Breast Cancer 21:1–10
6. Bouchardy C, Rapiiti E, Blagoevic S, Vlastos AT, Vlastos G (2007) Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 25:1858–1869
7. Turner N, Zafarana E, Sanna G, Mottino G, Biganzoli L (2013) The best treatment for older patients with breast cancer. EJC Suppl 11:299–300
8. Schonberg MA, Freedman RA, Recht AR, Jacobson AR, Aliberti GM, Karamourtopoulos M, et al (2019) Developing a patient decision aid for women aged 70 and older with early stage, estrogen receptor positive, HER2 negative, breast cancer. J Geriatr Oncol. https://doi.org/10.1016/j.jgo.2019.05.004
9. Ring A, Harder H, Langridge C, Ballinger RS, Fallowfield LJ (2013) Adjuvant chemotherapy in elderly women with breast cancer (ACHoW): an observational study identifying MDT perceptions and barriers to decision making. Ann Oncol 24:1211–1219
10. Healthcare Quality Improvement Partnership. National audit of breast cancer in older patients (NABCOP): 2018 annual report, https://www.hqip.org.uk/resource/national-audit-of-breast-cancer-in-older-patients-2018-annual-report/. Accessed 17 July 2019
11. Jung KW, Won YJ, Kong HJ, Lee ES (2019) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2016. Cancer Res Treat 51:417–430
12. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alliano CM, et al (2019) Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. https://doi.org/10.3322/caac.21565
13. Jeon YW, Kang SH, Park MH, Lim W, Cho SH, Suh YJ (2015) Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer 15:865
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC Cancer staging manual, 7th edn. Springer, New York
15. Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ et al (2008) NCCN task force report: breast cancer in the older woman. J Natl Compr Canc Netw 6(Suppl 4):S1–S25 (quiz S6–7)
16. Mamtani A, Gonzalez JJ, Neo D, Slanez PJ, Houlihan MJ, Herold CI et al (2016) Early-stage breast cancer in the octogenarian: tumor characteristics, treatment choices, and clinical outcomes. Ann Surg Oncol 23:3371–3378
17. Alliot C (2005) Undertreatment of breast cancer in elderly women: contribution of a cancer registry. J Clin Oncol 23:4800–4801 (author reply 1–2)
18. Thurlimann B, Keshaviah A, Coates AS, Mouridse H, Mauriac L, Forbes JF et al (2005) A comparison of tamoxifen and tamofoxin in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757
19. Cuzick J, Sestak I, Baum M, Budzard A, Howell A, Dowsett M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141
20. Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejertsen B, De Azambuja E et al (2019) Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1–98 trial. J Clin Oncol 37:105–114
21. Early Breast Cancer Clinical Trials’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
22. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B et al (2013) Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 31:2382–2387
23. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM (2015) Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 16:266–273
24. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366:2087–2106
25. Giordano SH, Pinder M, Duan Z, Hortobagyi G, Goodwin J (2006) Congestive heart failure (CHF) in older women treated with anthracycline (A) chemotherapy (C). J Clin Oncol 24:5218–5224
26. Patt DA, Duan Z, Fang S, Hortobagyi GN, Giordano SH (2007) Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25:3871–3876
27. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC et al (2012) Comparison of polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 380:2087–2106
28. Ward SE, Holmes GR, Ring A, Richards PD, Morgan JL, Broglio JW et al (2019) Adjuvant chemotherapy for breast cancer in older women: an analysis of retrospective English cancer registration data. Clin Oncol (R Coll Radiol) 31:444–452

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.